Home›Trial›NCT07255404
NCT07255404Phase 2RECRUITING

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Study Summary

This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment naïve), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function. Participants will receive pumitamig (BNT327) in combination with chemotherapy.

Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions / Drugs
PumitamigNab-paclitaxelGemcitabinemFOLFIRINOX
View on ClinicalTrials.gov ↗
Sponsor
BNTX
BioNTech SE
mRNA Therapeutics
F20/100
Study Details
Enrollment105 participants
Primary Completion—
Lead SponsorBioNTech SE
Data Retrieved2026-04-11 02:55:25.057663+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 105 participants
Sponsor Catalyst Profile

BioNTech SE (BNTX) is the sponsoring company for this trial. BiotechSign currently grades this company F (20/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BNTX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.